[go: up one dir, main page]

PL3768684T3 - Oksazynowe inhibitory lipazy monoacyloglicerolowej (magl) - Google Patents

Oksazynowe inhibitory lipazy monoacyloglicerolowej (magl)

Info

Publication number
PL3768684T3
PL3768684T3 PL19711920.9T PL19711920T PL3768684T3 PL 3768684 T3 PL3768684 T3 PL 3768684T3 PL 19711920 T PL19711920 T PL 19711920T PL 3768684 T3 PL3768684 T3 PL 3768684T3
Authority
PL
Poland
Prior art keywords
magl
oxazine
inhibitors
monoacylglycerol lipase
monoacylglycerol
Prior art date
Application number
PL19711920.9T
Other languages
English (en)
Inventor
Charles Bell
Joerg Benz
Luca Gobbi
Uwe Grether
Katrin Groebke Zbinden
Dennis Jul HANSEN
Benoit Hornsperger
Buelent Kocer
Carsten KROLL
Bernd Kuhn
Fionn O`HARA
Hans Richter
Martin Ritter
Satoshi Tsuchiya
Rui Chen
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3768684T3 publication Critical patent/PL3768684T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL19711920.9T 2018-03-22 2019-03-22 Oksazynowe inhibitory lipazy monoacyloglicerolowej (magl) PL3768684T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18163273 2018-03-22
CN2019075372 2019-02-18
PCT/EP2019/057174 WO2019180185A1 (en) 2018-03-22 2019-03-22 Oxazine monoacylglycerol lipase (magl) inhibitors

Publications (1)

Publication Number Publication Date
PL3768684T3 true PL3768684T3 (pl) 2023-07-10

Family

ID=65818027

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19711920.9T PL3768684T3 (pl) 2018-03-22 2019-03-22 Oksazynowe inhibitory lipazy monoacyloglicerolowej (magl)

Country Status (27)

Country Link
US (2) US20210107920A1 (pl)
EP (1) EP3768684B1 (pl)
JP (1) JP7308220B2 (pl)
KR (1) KR20200136425A (pl)
CN (1) CN111936503B (pl)
AU (1) AU2019238381B2 (pl)
BR (1) BR112020014992A2 (pl)
CA (1) CA3089443A1 (pl)
CL (1) CL2020002423A1 (pl)
CO (1) CO2020009567A2 (pl)
CR (1) CR20200416A (pl)
DK (1) DK3768684T3 (pl)
ES (1) ES2942319T3 (pl)
FI (1) FI3768684T3 (pl)
HR (1) HRP20230388T1 (pl)
HU (1) HUE061584T2 (pl)
IL (1) IL276031B2 (pl)
LT (1) LT3768684T (pl)
MX (1) MX2020008894A (pl)
PE (1) PE20201185A1 (pl)
PH (1) PH12020500661A1 (pl)
PL (1) PL3768684T3 (pl)
RS (1) RS64156B1 (pl)
SG (1) SG11202007608UA (pl)
SI (1) SI3768684T1 (pl)
TW (1) TWI818967B (pl)
WO (1) WO2019180185A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
CN111386269A (zh) 2017-11-28 2020-07-07 豪夫迈·罗氏有限公司 新型杂环化合物
EP3737680A1 (en) 2018-01-08 2020-11-18 F. Hoffmann-La Roche AG Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
PE20211089A1 (es) * 2018-08-13 2021-06-14 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
US20210094971A1 (en) * 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
MX2022002311A (es) * 2019-09-12 2022-03-25 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
PE20221450A1 (es) * 2019-09-23 2022-09-21 Hoffmann La Roche Compuestos heterociclicos
CN114514233A (zh) * 2019-09-24 2022-05-17 豪夫迈·罗氏有限公司 用于单酰基甘油脂肪酶(magl)的荧光探针
AU2020354414A1 (en) * 2019-09-24 2022-02-17 F. Hoffmann-La Roche Ag New heterocyclic monoacylglycerol lipase (MAGL) inhibitors
US20210094972A1 (en) * 2019-09-24 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
WO2022049134A1 (en) 2020-09-03 2022-03-10 F. Hoffmann-La Roche Ag Heterocyclic compounds
US20240408064A1 (en) * 2021-10-15 2024-12-12 Genetolead Inc. Ras inhibitors, compositions and methods of use thereof
MX2024008337A (es) 2021-12-29 2024-07-30 Psy Therapeutics Inc Inhibicion de la monoacilglicerol lipasa (magl).
WO2023247670A1 (en) * 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag New heterocyclic-carbonyl-cyclic compounds as magl inhibitors
TW202415651A (zh) 2022-07-29 2024-04-16 日商住友製藥股份有限公司 含氮飽和雜環衍生物
CN119894887A (zh) * 2022-09-20 2025-04-25 豪夫迈·罗氏有限公司 用于magl的荧光探针
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
US7408066B2 (en) 2005-06-20 2008-08-05 Schering Corproation Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
WO2007098418A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
US7872028B2 (en) 2006-04-05 2011-01-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
US9493451B2 (en) 2011-05-16 2016-11-15 Bionomics Limited Amine derivatives as potassium channel blockers
PL2800565T3 (pl) * 2012-01-06 2020-09-21 Lundbeck La Jolla Research Center, Inc. Związki karbaminianowe i sposoby ich wytwarzania oraz zastosowanie
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
JP2018515612A (ja) 2015-05-13 2018-06-14 セルビタ スプウカ アクツィーナ 置換キノキサリン誘導体
CA3199601A1 (en) 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
CN105198903B (zh) * 2015-11-09 2016-08-24 代先慧 一种治疗急性上呼吸道感染的药物组合物
WO2017170830A1 (ja) * 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
JP2021517575A (ja) 2021-07-26
EP3768684A1 (en) 2021-01-27
PE20201185A1 (es) 2020-11-03
MX2020008894A (es) 2020-10-12
RS64156B1 (sr) 2023-05-31
TWI818967B (zh) 2023-10-21
CA3089443A1 (en) 2019-09-26
IL276031B2 (en) 2023-06-01
AU2019238381A1 (en) 2020-08-06
BR112020014992A2 (pt) 2020-12-29
US20230117324A1 (en) 2023-04-20
CN111936503A (zh) 2020-11-13
AU2019238381B2 (en) 2022-07-07
CR20200416A (es) 2020-10-26
SG11202007608UA (en) 2020-09-29
LT3768684T (lt) 2023-04-25
SI3768684T1 (sl) 2023-06-30
JP7308220B2 (ja) 2023-07-13
FI3768684T3 (fi) 2023-04-26
KR20200136425A (ko) 2020-12-07
RU2020133991A (ru) 2022-04-22
CO2020009567A2 (es) 2020-08-10
IL276031A (en) 2020-08-31
HUE061584T2 (hu) 2023-07-28
US20210107920A1 (en) 2021-04-15
WO2019180185A8 (en) 2020-10-22
TW202003525A (zh) 2020-01-16
DK3768684T3 (da) 2023-04-24
ES2942319T3 (es) 2023-05-31
WO2019180185A1 (en) 2019-09-26
HRP20230388T1 (hr) 2023-06-23
PH12020500661A1 (en) 2021-06-28
EP3768684B1 (en) 2023-02-22
CN111936503B (zh) 2023-09-12
CL2020002423A1 (es) 2021-02-19

Similar Documents

Publication Publication Date Title
IL276031A (en) oxazine monoacylglycerol lipase (magl) inhibitors
ZA202006327B (en) Magl inhibitors
IL279173A (en) Heterocyclic compounds as monoacylglycerol lipase inhibitors
IL280762A (en) Heterocyclic compounds as monoacylglycerol lipase inhibitors
IL289594A (en) Heterocyclic monoacylglycerol lipase (magl) inhibitors
IL288936A (en) Heterocyclic monoacylglycerol lipase (magl) inhibitors
SG11202102281VA (en) Monoacylglycerol lipase modulators
ZA201905934B (en) Dual magl and faah inhibitors
IL276013A (en) pi4kiiibeta inhibitors
ZA202007357B (en) Lipolytic enzyme variants
PT3768684T (pt) Inibidores de oxazina da monoacilglicerol lipase (magl)
GB2587631B (en) An injection lance
PT3894132T (pt) Um eletrofuso
PL3894133T3 (pl) Elektrowrzeciono
HK40047049A (en) Magl inhibitors
MC200226B1 (fr) Brique de retenue
GB201903621D0 (en) Wooltop technology
GB201812462D0 (en) Inhibitors
GB201801832D0 (en) Furnace
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors